A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2

American Journal of Translational Research

Volumn 6, Issue 5, 2014, Pages 471-493

  Petrilli, Alejandra M ^a   Fuse, Marisa A ^a   Donnan, Mathew S ^a   Bott, Marga ^a   Sparrow, Nicklaus A ^a   Tondera, Daniel ^c,d   Huffziger, Julia ^c   Frenzel, Corina ^c   Siobhan Malany, C ^b   Echeverri, Christophe J ^c   Smith, Layton ^b   Fernández Valle, Cristina ^a  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^b BURNHAM INSTITUTE   (United States)

^c Cenix BioScience GmbH   (Germany)

^d Silence Therapeutics GmbH   (Germany)

Author keywords

Apoptosis; Autophagy; Neurofibromatosis type 2; phenotypic high throughput screen; PI3K; PI3K inhibitor

Indexed keywords

2 [4 [2 [3 CYCLOHEXYL 1 (4 CYCLOHEXYLBUTYL) UREIDO] ETHYL] PHENYLTHIO] 2 METHYLPROPIONIC ACID; 3 (3, 5 DIBROMO 4 HYDROXYBENZYLIDENE) 1, 3 DIHYDRO 5 IODO 2 INDOLONE; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2, 2 DIMETHYLPROPIONIC ACID; 5 (6 QUINOXALINYLMETHYLENE) 2, 4 THIAZOLIDINEDIONE; AC 93253 IODIDE; ANTINEOPLASTIC AGENT; BNTX MALEATE SALT HYDRATE; CANTHARIDIN; CASPASE; CGP 74514A; COMPACTIN; EBASTINE; FLUPHENAZINE; HALOPERIDOL; HISTONE DEACETYLASE; L 703606 OXALATE SALT HYDRATE; MIBEFRADIL DIHYDROCHLORIDE HYDRATE; MITOXANTRONE; N [(5 BROMO 2 METHOXYPHENYL) SULFONYL] 3 [2 (2 NAPHTHYLMETHYL) PHENYL] ACRYLAMIDE; PD 161570; PD 407824; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PICTILISIB; SALMETEROL XINAFOATE; SPIPERONE; STAUROSPORINE; THIORIDAZINE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOPHAGY; BIOASSAY; CELL PROLIFERATION; CELL VIABILITY; CELL VIABILITY ASSAY; CONTROLLED STUDY; DRUG TARGETING; EXPRESSION VECTOR; GENETIC TRANSDUCTION; HIGH THROUGHPUT SCREENING; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MEMBRANE ASYMMETRY ASSAY; MOUSE; NEUROFIBROMATOSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PROCESS OPTIMIZATION; SCHWANN CELL; SCHWANN CELL CULTURE; VALIDATION PROCESS; WESTERN BLOTTING;

EID: 84908070832     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Baser ME; Contributors to the International NF2 Mutation Database. The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene. Hum Mutat 2006; 27: 297-306.
2. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fi­bromatosis type 2. Nature 1993; 363: 515-521.
3. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993; 75: 826.
4. Evans DG. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis 2009; 4: 16.
5. Tsukita S, Oishi K, Sato N, Sagara J, Kawai A and Tsukita S. ERM family members as mo­lecular linkers between the cell surface glyco­protein CD44 and actin-based cytoskeletons. J Cell Biol 1994; 126: 391-401.
6. Stamenkovic I and Yu Q. Merlin, a “magic” link­er between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. Curr Protein Pept Sci 2010; 11: 471-484.
7. Giovannini M, Robanus-Maandag E, van der Valk M, Niwa-Kawakita M, Abramowski V, Goutebroze L, Woodruff JM, Berns A and Thomas G. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of hu­man neurofibromatosis type 2. Genes Dev 2000; 14: 1617-1630.
8. Gautreau A, Manent J, Fievet B, Louvard D, Giovannini M and Arpin M. Mutant products of the NF2 tumor suppressor gene are degraded by the ubiquitin-proteasome pathway. J Biol Chem 2002; 277: 31279-31282.
9. Manetti ME, Geden S, Bott M, Sparrow N, Lambert S and Fernandez-Valle C. Stability of the tumor suppressor merlin depends on its ability to bind paxillin LD3 and associate with beta1 integrin and actin at the plasma mem­brane. Biol Open 2012; 1: 949-957.
10. Yang C, Asthagiri AR, Iyer RR, Lu J, Xu DS, Ksendzovsky A, Brady RO, Zhuang Z and Lonser RR. Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function. Proc Natl Acad Sci U S A 2011; 108: 4980-4985.
11. Rong R, Tang X, Gutmann DH and Ye K. Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proc Natl Acad Sci U S A 2004; 101: 18200-18205.
12. Ye K, Hurt KJ, Wu FY, Fang M, Luo HR, Hong JJ, Blackshaw S, Ferris CD and Snyder SH. Pike. A nuclear gtpase that enhances PI3kinase activ­ity and is regulated by protein 4.1N. Cell 2000; 103: 919-930.
13. Hilton DA, Ristic N and Hanemann CO. Activation of ERK, AKT and JNK signalling path­ways in human schwannomas in situ. Histopathology 2009; 55: 744-749.
14. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-1657.
15. Jiang BH and Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 2009; 102: 19-65.
16. Stokoe D. The phosphoinositide 3-kinase path­way and cancer. Expert Rev Mol Med 2005; 7: 1-22.
17. Leevers SJ, Vanhaesebroeck B and Waterfield MD. Signalling through phosphoinositide 3-ki­nases: the lipids take centre stage. Curr Opin Cell Biol 1999; 11: 219-225.
18. Kok K, Nock GE, Verrall EA, Mitchell MP, Hommes DW, Peppelenbosch MP and Van-haesebroeck B. Regulation of p110delta PI 3-kinase gene expression. PLoS One 2009; 4: e5145.
19. Metjian A, Roll RL, Ma AD and Abrams CS. Agonists cause nuclear translocation of phos­phatidylinositol 3-kinase gamma. A Gbeta-gamma-dependent pathway that requires the p110gamma amino terminus. J Biol Chem 1999; 274: 27943-27947.
20. Wymann MP and Pirola L. Structure and func­tion of phosphoinositide 3-kinases. Biochim Biophys Acta 1998; 1436: 127-150.
21. Akinleye A, Avvaru P, Furqan M, Song Y and Liu D. Phosphatidylinositol 3-kinase (PI3K) inhibi­tors as cancer therapeutics. J Hematol Oncol 2013; 6: 88.
22. Petrilli A, Copik A, Posadas M, Chang LS, Welling DB, Giovannini M and Fernandez-Valle C. LIM domain kinases as potential therapeu­tic targets for neurofibromatosis type 2. Oncogene 2013; 33: 3571-82.
23. Thaxton C, Bott M, Walker B, Sparrow NA, Lambert S and Fernandez-Valle C. Schwan-nomin/merlin promotes Schwann cell elonga­tion and influences myelin segment length. Mol Cell Neurosci 2011; 47: 1-9.
24. Zhang JH, Chung TD and Oldenburg KR. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 1999; 4: 67-73.
25. Mayr LM and Bojanic D. Novel trends in high-throughput screening. Curr Opin Pharmacol 2009; 9: 580-588.
26. Giovannini M, Bonne NX, Vitte J, Chareyre F, Tanaka K, Adams R, Fisher LM, Valeyrie-Allanore L, Wolkenstein P, Goutagny S and Kalamarides M. mTORC1 inhibition delays growth of neurofibromatosis type 2 schwanno­ma. Neuro Oncol 2014; 16: 493-504.
27. James MF, Stivison E, Beauchamp R, Han S, Li H, Wallace MR, Gusella JF, Stemmer-Ra-chamimov AO and Ramesh V. Regulation ofmTOR complex 2 signaling in neurofibromato­sis 2-deficient target cell types. Mol Cancer Res 2012; 10: 649-659.
28. Kang YA, Kanki T, Kanneganti TD, Kanno H, Kanthasamy AG, Kanthasamy A, Karantza V, Kaushal GP, Kaushik S, Kawazoe Y, Ke PY, Kehrl JH, Kelekar A, Kerkhoff C, Kessel DH, Khalil H, Kiel JA, Kiger AA, Kihara A, Kim DR, Kim DH, Kim EK, Kim HR, Kim JS, Kim JH, Kim JC, Kim JK, Kim PK, Kim SW, Kim YS, Kim Y, Kimchi A, Kimmelman AC, King JS, Kinsella TJ, Kirkin V, Kirshenbaum LA, Kitamoto K, Kitazato K, Klein L, Klimecki WT, Klucken J, Knecht E, Ko BC, Koch JC, Koga H, Koh JY, Koh YH, Koike M, Komatsu M, Kominami E, Kong HJ, Kong WJ, Korolchuk VI, Kotake Y, Koukourakis MI, Kouri Flores JB, Kovacs AL, Kraft C, Krainc D, Kramer H, Kretz-Remy C, Krichevsky AM, Kroemer G, Kruger R, Krut O, Ktistakis NT, Kuan CY, Kucharczyk R, Kumar A, Kumar R, Kumar S, Kundu M, Kung HJ, Kurz T, Kwon HJ, La Spada AR, Lafont F, Lamark T, Landry J, Lane JD, Lapaquette P, Laporte JF, Laszlo L, Lavandero S, Lavoie JN, Layfield R, Lazo PA, Le W, Le Cam L, Ledbetter DJ, Lee AJ, Lee BW, Lee GM, Lee J, Lee JH, Lee M, Lee MS, Lee SH, Leeuwenburgh C, Legembre P, Legouis R, Lehmann M, Lei HY, Lei QY, Leib DA, Leiro J, Lemasters JJ, Lemoine A, Lesniak MS, Lev D, Levenson VV, Levine B, Levy E, Li F, Li JL, Li L, Li S, Li W, Li XJ, Li YB, Li YP, Liang C, Liang Q, Liao YF, Liberski PP, Lieberman A, Lim HJ, Lim KL, Lim K, Lin CF, Lin FC, Lin J, Lin JD, Lin K, Lin WW, Lin WC, Lin YL, Linden R, Lingor P, Lippincott-Schwartz J, Lisanti MP, Liton PB, Liu B, Liu CF, Liu K, Liu L, Liu QA, Liu W, Liu YC, Liu Y, Lockshin RA, Lok CN, Lonial S, Loos B, Lopez-Berestein G, Lopez-Otin C, Lossi L, Lotze MT, Low P, Lu B, Lu Z, Luciano F, Lukacs NW, Lund AH, Lynch-Day MA, Ma Y, Macian F, MacKeigan JP, Macleod KF, Madeo F, Maiuri L, Maiuri MC, Malagoli D, Malicdan MC, Malorni W, Man N, Mandelkow EM, Manon S, Manov I, Mao K, Mao X, Mao Z, Marambaud P, Marazziti D, Marcel YL, Marchbank K, Marchetti P, Marciniak SJ, Marcondes M, Mardi M, Marfe G, Marino G, Markaki M, Marten MR, Martin SJ, Martinand-Mari C, Martinet W, Martinez-Vicente M, Masini M, Matarrese P, Matsuo S, Matteoni R, Mayer A, Mazure NM, McConkey DJ, McConnell MJ, McDermott C, McDonald C, McInerney GM, McKenna SL, McLaughlin B, McLean PJ, McMaster CR, McQuibban GA, Meijer AJ, Meisler MH, Melendez A, Melia TJ, Xie Z, Xu DZ, Xu J, Xu L, Xu X, Yamamoto A, Yamashina S, Yamashita M, Yan X, Yanagida M, Yang DS, Yang E, Yang JM, Yang SY, Yang W, Yang WY, Yang Z, Yao MC, Yao TP, Yeganeh B, Yen WL, Yin JJ, Yin XM, Yoo OJ, Yoon G, Yoon SY, Yorimitsu T, Yoshikawa Y, Yoshimori T, Yoshimoto K, You HJ, Youle RJ, Younes A, Yu L, Yu SW, Yu WH, Yuan ZM, Yue Z, Yun CH, Yuzaki M, Zabirnyk O, Silva-Zacarin E, Zacks D, Zacksenhaus E, Zaffaroni N, Zakeri Z, Zeh HJ, Zeitlin SO, Zhang H, Zhang HL, Zhang J, Zhang JP, Zhang L, Zhang MY, Zhang XD, Zhao M, Zhao YF, Zhao Y, Zhao ZJ, Zheng X, Zhivotovsky B, Zhong Q, Zhou CZ, Zhu C, Zhu WG, Zhu XF, Zhu X, Zhu Y, Zoladek T, Zong WX, Zorzano A, Zschocke J and Zuckerbraun B. Guidelines for the use and interpretation of as­says for monitoring autophagy. Autophagy 2012; 8: 445-544.
29. Sadhu C, Masinovsky B, Dick K, Sowell CG and Staunton DE. Essential role of phosphoinosit­ide 3-kinase delta in neutrophil directional movement. J Immunol 2003; 170: 2647-2654.
30. Petrilli A, Bott M and Fernandez-Valle C. Inhibition of SIRT2 in merlin/NF2-mutant Schwann cells triggers necrosis. Oncotarget 2013; 4: 2354-2365.
31. Graziano MJ and Casida JE. Comparison of the acute toxicity of endothal and cantharidic acid on mouse liver in vivo. Toxicol Lett 1987; 37: 143-148.
32. Camps M, Ruckle T, Ji H, Ardissone V, Rintelen F, Shaw J, Ferrandi C, Chabert C, Gillieron C, Francon B, Martin T, Gretener D, Perrin D, Leroy D, Vitte PA, Hirsch E, Wymann MP, Cirillo R, Schwarz MK and Rommel C. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 2005; 11: 936-943.
33. Mielcke TR, Mascarello A, Filippi-Chiela E, Zanin RF, Lenz G, Leal PC, Chiaradia LD, Yunes RA, Nunes RJ, Battastini AM, Morrone FB and Campos MM. Activity of novel quinoxaline-de­rived chalcones on in vitro glioma cell prolifera­tion. Eur J Med Chem 2012; 48: 255-264.
34. Spitzenberg V, Konig C, Ulm S, Marone R, Ropke L, Muller JP, Grun M, Bauer R, Rubio I, Wymann MP, Voigt A and Wetzker R. Targeting PI3K in neuroblastoma. J Cancer Res Clin Oncol 2010; 136: 1881-1890.
35. Duronio V. The life of a cell: apoptosis regula­tion by the PI3K/PKB pathway. Biochem J 2008; 415: 333-344.
36. Lallemand D, Manent J, Couvelard A, Watilliaux A, Siena M, Chareyre F, Lampin A, Niwa-Kawakita M, Kalamarides M and Giovannini M. Merlin regulates transmembrane receptor ac­cumulation and signaling at the plasma mem­brane in primary mouse Schwann cells and in human schwannomas. Oncogene 2009; 28: 854-865.
37. Li Y, Tennekoon GI, Birnbaum M, Marchionni MA and Rutkowski JL. Neuregulin signaling through a PI3K/Akt/Bad pathway in Schwann cell survival. Mol Cell Neurosci 2001; 17: 761-767.
38. Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ and Shuttleworth SJ. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a po­tent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008; 51: 5522-5532.
39. Ohwada J, Ebiike H, Kawada H, Tsukazaki M, Nakamura M, Miyazaki T, Morikami K, Yoshinari K, Yoshida M, Kondoh O, Kuramoto S, Ogawa K, Aoki Y and Shimma N. Discovery and bio­logical activity of a novel class I PI3K inhibitor, CH5132799. Bioorg Med Chem Lett 2011; 21: 1767-1772.
40. Talekar M, Ganta S, Singh A, Amiji M, Kendall J, Denny WA and Garg S. Phosphatidylinositol 3-kinase inhibitor (PIK75) containing surface functionalized nanoemulsion for enhanced drug delivery, cytotoxicity and pro-apoptotic ac­tivity in ovarian cancer cells. Pharm Res 2012; 29: 2874-2886.
41. Tanaka H, Yoshida M, Tanimura H, Fujii T, Sakata K, Tachibana Y, Ohwada J, Ebiike H, Kuramoto S, Morita K, Yoshimura Y, Yamazaki T, Ishii N, Kondoh O and Aoki Y. The selective class I PI3K inhibitor CH5132799 targets hu­man cancers harboring oncogenic PIK3CA mu­tations. Clin Cancer Res 2011; 17: 3272-3281.
42. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK and Sawyers CL. Antitumor ac­tivity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008; 5: e8.
43. Liu P, Cheng H, Roberts TM and Zhao JJ. Targeting the phosphoinositide 3-kinase path­way in cancer. Nat Rev Drug Discov 2009; 8: 627-644.
44. Maira SM, Stauffer F, Schnell C and Garcia-Echeverria C. PI3K inhibitors for cancer treat­ment: where do we stand? Biochem Soc Trans 2009; 37: 265-272.
45. Leung E, Kim JE, Rewcastle GW, Finlay GJ and Baguley BC. Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells. Cancer Biol Ther 2011; 11: 938-946.
46. Qian C, Lai CJ, Bao R, Wang DG, Wang J, Xu GX, Atoyan R, Qu H, Yin L, Samson M, Zifcak B, Ma AW, DellaRocca S, Borek M, Zhai HX, Cai X and Voi M. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. Clin Cancer Res 2012; 18: 4104-4113.